|
515 Companies |
|
302 Products |
|
302 Products |
|
167 Mechanisms of Action |
|
1404 Trials |
|
125634 News |
|
| «12...15241525152615271528152915301531153215331534...15771578» |
- |||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open: Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 (clinicaltrials.gov) - Feb 24, 2016
P2b, N=58, Enrolling by invitation, Sponsor: Medical Research Council
Active, not recruiting --> Enrolling by invitation
- doxorubicin hydrochloride / Generic mfg., dexrazoxane / Generic mfg.
Enrollment open, Head-to-Head, Metastases: Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Feb 24, 2016
P2, N=73, Recruiting, Sponsor: Washington University School of Medicine
Active, not recruiting --> Enrolling by invitation Not yet recruiting --> Recruiting
- | Keytruda (pembrolizumab) / Merck (MSD)
New P2 trial, Surgery: A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery (clinicaltrials.gov) - Feb 24, 2016
P2, N=18, Not yet recruiting, Sponsor: Oslo University Hospital
- Biomarker, Trial completion: Genetic Biomarkers in Tissue Samples From Patients With Osteosarcoma (clinicaltrials.gov) - Feb 24, 2016
P=N/A, N=10, Completed, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Trial primary completion date, Metastases: Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer (clinicaltrials.gov) - Feb 23, 2016
P2, N=299, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial primary completion date: Feb 2016 --> Jun 2016
- || topotecan / Generic mfg., cyclophosphamide / Generic mfg., vincristine / Generic mfg.
Trial suspension, Metastases: AEWS1031: Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma (clinicaltrials.gov) - Feb 23, 2016
P3, N=693, Suspended, Sponsor: Children's Oncology Group
Trial primary completion date: Feb 2016 --> Jun 2016 Recruiting --> Suspended
- Biomarker, Enrollment change, Trial withdrawal: Biomarker Study in Samples From Patients With Malignant Rhabdoid Tumor of the Kidney or Atypical Teratoid Rhabdoid Tumor (clinicaltrials.gov) - Feb 23, 2016
P=N/A, N=0, Withdrawn, Sponsor: Children's Oncology Group
Recruiting --> Suspended N=20 --> 0 | Active, not recruiting --> Withdrawn
- Calsed (amrubicin) / Sumitomo Pharma, BMS
Trial completion, Enrollment change, Trial primary completion date, Metastases: ARSARC-PI-0010: Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma (clinicaltrials.gov) - Feb 23, 2016
P2, N=24, Completed, Sponsor: University of Utah
N=20 --> 0 | Active, not recruiting --> Withdrawn Active, not recruiting --> Completed | N=30 --> 24 | Trial primary completion date: Jan 2017 --> Feb 2016
- temozolomide / Generic mfg., erlotinib / Generic mfg.
New P2 trial, Combination therapy: Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors (clinicaltrials.gov) - Feb 23, 2016
P2, N=30, Not yet recruiting, Sponsor: Washington University School of Medicine
- Enrollment closed, Trial primary completion date: DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With High-risk Soft Tissue Sarcoma (clinicaltrials.gov) - Feb 22, 2016
P1/2, N=30, Active, not recruiting, Sponsor: Affiliated Hospital to Academy of Military Medical Sciences
Active, not recruiting --> Completed | N=30 --> 24 | Trial primary completion date: Jan 2017 --> Feb 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Dec 2016
- Keytruda (pembrolizumab) / Merck (MSD)
Trial primary completion date, Metastases: Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) (clinicaltrials.gov) - Feb 22, 2016
P1/2, N=90, Recruiting, Sponsor: Western Regional Medical Center
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Dec 2015 --> Dec 2016
- | Intuvax (ilixadencel) / Mendus
New P1 trial, Stroma: A Study to Evaluate the Safety of Intuvax Administered Intra-tumorally in Patients With Gastrointestinal Stromal Tumors (clinicaltrials.gov) - Feb 22, 2016
P1, N=12, Not yet recruiting, Sponsor: Immunicum AB
- Trial completion, Surgery, Stroma, Metastases: Laparoscopic Resection of Large Gastric Stromal Tumors (clinicaltrials.gov) - Feb 21, 2016
P=N/A, N=23, Completed, Sponsor: Medical Park Gaziantep Hospital
Trial primary completion date: Dec 2015 --> Dec 2016 Enrolling by invitation --> Completed
- || Votrient (pazopanib) / Novartis, BeiGene
Trial primary completion date, Metastases: Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial (clinicaltrials.gov) - Feb 21, 2016
P2, N=52, Active, not recruiting, Sponsor: Grupo Espanol de Investigacion en Sarcomas
Enrolling by invitation --> Completed Trial primary completion date: Dec 2015 --> Dec 2016
- || Trial primary completion date, Stroma: Symptom Inventory for Gastrointestinal Stromal Tumors (clinicaltrials.gov) - Feb 21, 2016
P=N/A, N=188, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Jul 2016 --> Jul 2017
- glembatumumab vedotin (CDX-011) / Celldex
Enrollment open: AOST1521: Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma (clinicaltrials.gov) - Feb 21, 2016
P2, N=38, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2016 --> Jul 2017 Not yet recruiting --> Recruiting
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, Review, Journal, PD(L)-1 Biomarker, Surgery, Metastases: Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Feb 21, 2016
P1, N=42, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- temozolomide / Generic mfg.
Enrollment change, IO biomarker: Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma (clinicaltrials.gov) - Feb 20, 2016
P2, N=54, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Recruiting N=30 --> 54
- Recentin (cediranib) / AstraZeneca
Enrollment closed, Combination therapy: SWOG S0905: Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma (clinicaltrials.gov) - Feb 18, 2016
P2, N=116, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=30 --> 54 Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche
Trial primary completion date, Combination therapy: Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor (clinicaltrials.gov) - Feb 17, 2016
P=N/A, N=15, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2016 --> Aug 2017
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Leukine (sargramostim) / Partner Therap
Trial suspension: Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma (clinicaltrials.gov) - Feb 17, 2016
P1/2, N=40, Suspended, Sponsor: Barbara Ann Karmanos Cancer Institute
Trial primary completion date: Aug 2016 --> Aug 2017 Active, not recruiting --> Suspended
- sunitinib / Generic mfg., Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
Trial initiation date, Trial primary completion date, Stroma: Ph II CABOGIST in GIST (clinicaltrials.gov) - Feb 17, 2016
P2, N=50, Not yet recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Suspended Initiation date: Jul 2015 --> May 2016 | Trial primary completion date: Jan 2016 --> Jan 2017
- bendamustine / Generic mfg.
Enrollment closed, Enrollment change: Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma (clinicaltrials.gov) - Feb 17, 2016
P2, N=45, Active, not recruiting, Sponsor: University of Washington
Initiation date: Jul 2015 --> May 2016 | Trial primary completion date: Jan 2016 --> Jan 2017 Recruiting --> Active, not recruiting | N=61 --> 45
- Keytruda (pembrolizumab) / Merck (MSD), Zaltrap (ziv-aflibercept IV) / Sanofi
Trial primary completion date, PD(L)-1 Biomarker, Metastases: Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer (clinicaltrials.gov) - Feb 17, 2016
P1, N=36, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | N=61 --> 45 Trial primary completion date: Jan 2016 --> Jul 2016
- topotecan / Generic mfg., cyclophosphamide / Generic mfg.
New P2 trial: Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors (clinicaltrials.gov) - Feb 17, 2016
P2, N=10, Recruiting, Sponsor: Nicklaus Children's Hospital f/k/a Miami Children's Hospital
- New P1/2 trial: DHEA in Synovial Sarcoma Patients (clinicaltrials.gov) - Feb 17, 2016
P1/2, N=47, Not yet recruiting, Sponsor: Washington University School of Medicine
- EGFR bi-armed autologous activated T cells / Barbara Ann Karmanos Cancer Institute
Enrollment change, Trial withdrawal: EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma (clinicaltrials.gov) - Feb 16, 2016
P1/2, N=0, Withdrawn, Sponsor: Barbara Ann Karmanos Cancer Institute
Trial primary completion date: Jan 2016 --> Jul 2016 N=57 --> 0 | Not yet recruiting --> Withdrawn
- sorafenib / Generic mfg.
Trial primary completion date: Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis (clinicaltrials.gov) - Feb 16, 2016
P3, N=83, Suspended, Sponsor: National Cancer Institute (NCI)
N=57 --> 0 | Not yet recruiting --> Withdrawn Trial primary completion date: Mar 2016 --> Mar 2017
- glembatumumab vedotin (CDX-011) / Celldex
Trial initiation date: AOST1521: Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma (clinicaltrials.gov) - Feb 16, 2016
P2, N=38, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Mar 2016 --> Mar 2017 Initiation date: Aug 2015 --> Apr 2016
- Iclusig (ponatinib) / Takeda, Otsuka
Trial primary completion date, Stroma, Metastases: A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (clinicaltrials.gov) - Feb 12, 2016
P2, N=45, Active, not recruiting, Sponsor: Ariad Pharmaceuticals
Initiation date: Aug 2015 --> Apr 2016 Trial primary completion date: Jun 2016 --> Feb 2015
- Yervoy (ipilimumab) / BMS
Trial primary completion date, Metastases: Ipilimumab and Imatinib Mesylate in Advanced Cancer (clinicaltrials.gov) - Feb 12, 2016
P1, N=96, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jun 2016 --> Feb 2015 Trial primary completion date: Feb 2017 --> Feb 2018
- || Avastin (bevacizumab) / Roche
Trial primary completion date, Combination therapy, Metastases: A Study of Avastin (Bevacizumab) in Combination With Standard Chemotherapy in Children and Adolescents With Sarcoma. (clinicaltrials.gov) - Feb 12, 2016
P2, N=154, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Feb 2017 --> Feb 2018 Trial primary completion date: May 2019 --> May 2015
- linsitinib (ASP7487) / VasaraGen
Trial completion, Enrollment change, Stroma: Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors (clinicaltrials.gov) - Feb 11, 2016
P2, N=20, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: May 2019 --> May 2015 Active, not recruiting --> Completed | N=40 --> 20
- Fragmin (dalteparin sodium) / Pfizer, Eisai, sunitinib / Generic mfg.
Trial primary completion date, Combination therapy, Surgery, Metastases: Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Feb 10, 2016
P1, N=16, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed | N=40 --> 20 Trial primary completion date: Nov 2014 --> Nov 2015
- decitabine / Generic mfg.
Enrollment closed, Enrollment change: Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma (clinicaltrials.gov) - Feb 10, 2016
P1, N=19, Active, not recruiting, Sponsor: University of Louisville
Trial primary completion date: Nov 2014 --> Nov 2015 Recruiting --> Active, not recruiting | N=15 --> 19
- Verzenio (abemaciclib) / Eli Lilly
Enrollment open: AflacST1501: Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors (clinicaltrials.gov) - Feb 10, 2016
P1, N=50, Recruiting, Sponsor: Cynthia Wetmore
Recruiting --> Active, not recruiting | N=15 --> 19 Not yet recruiting --> Recruiting
- methotrexate IV / Generic mfg.
Trial primary completion date, HEOR, Cost effectiveness: Outpatient Administration of High Dose Methotrexate (HD MTX) in Patients With Osteosarcoma (clinicaltrials.gov) - Feb 10, 2016
P3, N=12, Recruiting, Sponsor: The Hospital for Sick Children
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2015 --> Feb 2017
- || Inlyta (axitinib) / Pfizer, Torisel (temsirolimus) / Pfizer, Sutent (sunitinib) / Pfizer
Trial primary completion date, Stroma, Metastases: Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR] (clinicaltrials.gov) - Feb 9, 2016
P=N/A, N=1600, Recruiting, Sponsor: Pfizer
Trial primary completion date: Aug 2015 --> Feb 2017 Trial primary completion date: Sep 2016 --> Sep 2017
- Trial primary completion date: Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer (clinicaltrials.gov) - Feb 9, 2016
P2, N=131, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Sep 2016 --> Sep 2017 Trial primary completion date: Jan 2016 --> Jan 2017
- Trial initiation date, Trial primary completion date: Adoptive Therapy Using Antigen-Specific CD4 T-Cells (clinicaltrials.gov) - Feb 9, 2016
P1, N=12, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jan 2016 --> Jan 2017 Initiation date: Nov 2015 --> May 2016 | Trial primary completion date: Nov 2018 --> May 2019
- | Tasigna (nilotinib) / Novartis, Inhibikase
Enrollment closed, Enrollment change: Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study (clinicaltrials.gov) - Feb 9, 2016
P4, N=45, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Nov 2015 --> May 2016 | Trial primary completion date: Nov 2018 --> May 2019 Recruiting --> Active, not recruiting | N=300 --> 45
- | ifosfamide / Generic mfg., cisplatin / Generic mfg., mesna / Generic mfg.
Trial completion: Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus (clinicaltrials.gov) - Feb 9, 2016
P3, N=216, Completed, Sponsor: Gynecologic Oncology Group
Recruiting --> Active, not recruiting | N=300 --> 45 Active, not recruiting --> Completed
- zoledronic acid / Generic mfg.
Trial initiation date: Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors (clinicaltrials.gov) - Feb 9, 2016
P1, N=21, Recruiting, Sponsor: University of Wisconsin, Madison
Active, not recruiting --> Completed Initiation date: Sep 2015 --> Jan 2016
- |||||| Xpovio (selinexor) / Karyopharm
Enrollment open, Metastases: SEAL: Selinexor in Advanced Liposarcoma (clinicaltrials.gov) - Feb 9, 2016
P2/3, N=245, Recruiting, Sponsor: Karyopharm Therapeutics, Inc
Initiation date: Sep 2015 --> Jan 2016 Not yet recruiting --> Recruiting
- Leukine (sargramostim) / Partner Therap, Reolysin (pelareorep) / Oncolytics, Andrus Reo
Trial suspension, Combination therapy: Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors (clinicaltrials.gov) - Feb 5, 2016
P1, N=21, Suspended, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting Recruiting --> Suspended
- || Piqray (alpelisib) / Novartis
Trial primary completion date, Combination therapy, Stroma: A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients (clinicaltrials.gov) - Feb 4, 2016
P1, N=56, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Suspended Trial primary completion date: Dec 2015 --> Jul 2016
- || buparlisib (AN2025) / Novartis, Adlai Nortye
Trial primary completion date, Combination therapy, Stroma: A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients (clinicaltrials.gov) - Feb 4, 2016
P1, N=60, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2015 --> Jul 2016 Trial primary completion date: Dec 2015 --> Jul 2016
- humanised dinutuximab (Hu14.18K322A) / Essential Pharma
Trial primary completion date: A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma (clinicaltrials.gov) - Feb 4, 2016
P1, N=75, Recruiting, Sponsor: St. Jude Children's Research Hospital
Trial primary completion date: Dec 2015 --> Jul 2016 Trial primary completion date: Jun 2016 --> Jun 2017
- Recentin (cediranib) / AstraZeneca
Trial primary completion date, Combination therapy: Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Feb 4, 2016
P1/2, N=40, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2016 --> Jun 2017 Trial primary completion date: Mar 2016 --> Mar 2017
- Enrollment closed, Trial primary completion date: MALTED: Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases (clinicaltrials.gov) - Feb 4, 2016
P1, N=18, Active, not recruiting, Sponsor: Baylor College of Medicine
Trial primary completion date: Mar 2016 --> Mar 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2016 --> Mar 2015